关于将公平性考量纳入抗癌药物价值评估的探讨

Discussion On Equity Consideration In The Evaluation Of Anticancer Drugs

医疗保障是减轻群众就医负担、增进民生福祉、维护社会和谐稳定的重大制度安排。2017-2019年三次国家医保谈判准入工作创新引入卫生技术评估等,将多种抗癌药物纳入医保报销,为解除全体人民疾病医疗后顾之忧起到重要作用。而在决策中继续纳入公平性考量不仅是中央医保改革意见中的要求之一,也是全球卫生技术评估(HTA)的发展方向。本文通过重点文献调研方法,分析、阐述医保政策对临床结果的影响。在此基础上,借鉴当前世界上对报销决策公平性的研究经验,对我国抗癌药物价值评估的改进方向提出建议。

Healthcare security is an important institutional arrangement to reduce the burden of medical treatment,improve people's livelihood and maintain social harmony and stability.From 2017 to 2019,the three times of national healthcare security drug negotiation work innovation introduced health technology assessment,and a variety of anti-cancer drugs were included in the medical insurance reimbursement,which played an important role in relieving all people's worries about medical treatment.It is not only one of the requirements of healthcare security reform,but also the development direction of global health technology assessment(HTA).This paper analyzes the impact of healthcare security policy on clinical outcomes through key literature research methods.On this basis,drawing on the current research experience on fairness of reimbursement decision-making in the world,suggestions for improving the value evaluation of anti-cancer drugs in China are put forward.